Positive News Sentiment NASDAQ:TARS Tarsus Pharmaceuticals - TARS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $12.57 -0.09 (-0.71%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$12.44▼$12.9550-Day Range$11.92▼$16.2752-Week Range$10.80▼$19.66Volume110,085 shsAverage Volume74,724 shsMarket Capitalization$336.00 millionP/E RatioN/ADividend YieldN/APrice Target$41.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Tarsus Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside226.2% Upside$41.00 Price TargetShort InterestBearish5.40% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$822,740 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.82) to ($3.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.06 out of 5 starsMedical Sector512th out of 996 stocksBiological Products, Except Diagnostic Industry90th out of 165 stocks 3.5 Analyst's Opinion Consensus RatingTarsus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.00, Tarsus Pharmaceuticals has a forecasted upside of 226.2% from its current price of $12.57.Amount of Analyst CoverageTarsus Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted5.40% of the float of Tarsus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTarsus Pharmaceuticals has a short interest ratio ("days to cover") of 14.2, which indicates bearish sentiment.Change versus previous monthShort interest in Tarsus Pharmaceuticals has recently increased by 4.34%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldTarsus Pharmaceuticals does not currently pay a dividend.Dividend GrowthTarsus Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TARS. Previous Next 2.6 News and Social Media Coverage News SentimentTarsus Pharmaceuticals has a news sentiment score of 1.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Tarsus Pharmaceuticals this week, compared to 1 article on an average week.MarketBeat FollowsOnly 1 people have added Tarsus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tarsus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $822,740.00 in company stock.Percentage Held by Insiders33.08% of the stock of Tarsus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.82% of the stock of Tarsus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Tarsus Pharmaceuticals are expected to grow in the coming year, from ($4.82) to ($3.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tarsus Pharmaceuticals is -4.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tarsus Pharmaceuticals is -4.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTarsus Pharmaceuticals has a P/B Ratio of 1.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Tarsus Pharmaceuticals (NASDAQ:TARS) StockTarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.Read More Receive TARS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TARS Stock News HeadlinesMarch 22, 2023 | americanbankingnews.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) CEO Sells $10,557.60 in StockMarch 17, 2023 | finance.yahoo.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Expected To Breakeven In The Near FutureApril 2, 2023 | Vantage Point (Ad)What’s At Stake In April is ShockingThe Fed will be meeting on a topic that could change trading forever, and the decision could come as soon as the end of April. But by taking the smartest approach now, you can help shield your assets and work toward your trading goals. Time, as always, is of the essence. Click on this link to see what you need to do right away. March 15, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM), Tarsus Pharmaceuticals (TARS) and Decibel Therapeutics (DBTX)March 14, 2023 | finanznachrichten.deTarsus Pharmaceuticals, Inc: Tarsus Reports Full-Year 2022 Financial Results and Recent Business AchievementsMarch 14, 2023 | msn.comTarsus Pharmaceuticals GAAP EPS of -$2.52, revenue of $25.82MMarch 13, 2023 | finance.yahoo.comTarsus Reports Full-Year 2022 Financial Results and Recent Business AchievementsFebruary 24, 2023 | finance.yahoo.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insiders placed bullish bets worth US$1.6m in the last 12 monthsApril 2, 2023 | Legacy Research (Affiliate) (Ad)Sell every Stock except ONE Markets are down...But Jeff Clark couldn't care less because he ignores almost every stock in the market except ONE. He lives financially free trading this One Stock Once per month...January 24, 2023 | seekingalpha.comTarsus Pharma: Excellent Data, Nice Execution, Unclear Market PotentialDecember 22, 2022 | finanznachrichten.deTarsus Pharmaceuticals, Inc: Tarsus Added to NASDAQ Biotechnology IndexDecember 15, 2022 | finance.yahoo.comTarsus Pharma Touts Positive Data For Experimental Drug For Tick-Borne DiseaseDecember 15, 2022 | finance.yahoo.comTarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme DiseaseDecember 8, 2022 | finance.yahoo.comInstitutional investors own a significant stake of 41% in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)November 11, 2022 | finance.yahoo.comTarsus Pharmaceuticals Third Quarter 2022 Earnings: US$0.84 loss per share (vs US$0.76 loss in 3Q 2021)November 9, 2022 | msn.comTarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Misses Revenue EstimatesNovember 9, 2022 | finance.yahoo.comTarsus Reports Third Quarter 2022 Financial Results and Recent Business AchievementsOctober 25, 2022 | finance.yahoo.comTarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual MeetingOctober 17, 2022 | finance.yahoo.comTarsus Pharmaceuticals (NASDAQ:TARS) investors are sitting on a loss of 40% if they invested a year agoOctober 11, 2022 | finance.yahoo.comTarsus Announces Transition Plans for Board of DirectorsOctober 6, 2022 | finance.yahoo.comTarsus Appoints Scott Morrison as Board Member and Audit Committee ChairSeptember 29, 2022 | finance.yahoo.comTarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex BlepharitisSeptember 27, 2022 | finance.yahoo.comTarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care MeetingsSeptember 17, 2022 | finance.yahoo.comThe Chief Medical Advisor & Director of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), Elizabeth Lin, Just Bought A Few More SharesSeptember 7, 2022 | finance.yahoo.comTarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex BlepharitisAugust 24, 2022 | reuters.comTarsus Pharmaceuticals IncAugust 14, 2022 | nasdaq.comThe Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Second-Quarter Results Are Out And Analysts Have Published New ForecastsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TARS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TARS Company Calendar Last Earnings11/09/2021Today4/02/2023Next Earnings (Estimated)5/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TARS CUSIPN/A CIK1819790 Webwww.tarsusrx.com Phone949-409-9820FaxN/AEmployees46Year FoundedN/APrice Target and Rating Average Stock Price Forecast$41.00 High Stock Price Forecast$43.00 Low Stock Price Forecast$40.00 Forecasted Upside/Downside+226.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,090,000.00 Net Margins-324.99% Pretax Margin-240.53% Return on Equity-32.41% Return on Assets-27.64% Debt Debt-to-Equity Ratio0.10 Current Ratio14.61 Quick Ratio14.61 Sales & Book Value Annual Sales$25.82 million Price / Sales13.01 Cash FlowN/A Price / Cash FlowN/A Book Value$7.23 per share Price / Book1.74Miscellaneous Outstanding Shares26,730,000Free Float17,889,000Market Cap$336.00 million OptionableNot Optionable Beta0.69 Key ExecutivesDr. Bobak R. Azamian M.D.Co-Founder, Pres, CEO & ChairmanDr. Bryan Wahl J.D. (Age 44)M.D., Gen. Counsel & Corp. Sec. Comp: $545.52kMs. Dianne C. Whitfield M.S.W. (Age 45)Chief HR Officer Comp: $578.9kDr. Elizabeth Yeu Lin M.D. (Age 44)Chief Medical Advisor & Director Comp: $240kDr. D. Michael Ackermann Ph.D. (Age 40)Consultant Comp: $130kMr. Leonard M. Greenstein J.D. (Age 46)Chief Financial Officer Dr. Seshadri Neervannan Ph.D. (Age 54)Chief Operating Officer Mr. David NakasoneHead of Investor RelationsMs. Adrienne KempSr. Director of Corp. CommunicationsMr. Matthew Rossen M.B.A. (Age 45)VP of Marketing More ExecutivesKey CompetitorsAura BiosciencesNASDAQ:AURAVoyager TherapeuticsNASDAQ:VYGRDBV TechnologiesNASDAQ:DBVTCaribou BiosciencesNASDAQ:CRBUHumacyteNASDAQ:HUMAView All CompetitorsInsiders & InstitutionsSeshadri NeervannanSold 379 sharesTotal: $4,790.56 ($12.64/share)Leonard M GreensteinSold 332 sharesTotal: $4,196.48 ($12.64/share)Bryan WahlSold 357 sharesTotal: $4,512.48 ($12.64/share)Bobak R AzamianSold 709 sharesTotal: $8,961.76 ($12.64/share)Jose M TrevejoSold 529 sharesTotal: $6,686.56 ($12.64/share)View All Insider TransactionsView All Institutional Transactions TARS Stock - Frequently Asked Questions Should I buy or sell Tarsus Pharmaceuticals stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tarsus Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" TARS shares. View TARS analyst ratings or view top-rated stocks. What is Tarsus Pharmaceuticals' stock price forecast for 2023? 2 Wall Street research analysts have issued twelve-month target prices for Tarsus Pharmaceuticals' stock. Their TARS share price forecasts range from $40.00 to $43.00. On average, they anticipate the company's stock price to reach $41.00 in the next year. This suggests a possible upside of 226.2% from the stock's current price. View analysts price targets for TARS or view top-rated stocks among Wall Street analysts. How have TARS shares performed in 2023? Tarsus Pharmaceuticals' stock was trading at $14.66 at the beginning of 2023. Since then, TARS shares have decreased by 14.3% and is now trading at $12.57. View the best growth stocks for 2023 here. When is Tarsus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our TARS earnings forecast. How were Tarsus Pharmaceuticals' earnings last quarter? Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) announced its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.76) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by $0.34. The firm earned $1.24 million during the quarter, compared to analysts' expectations of $1 million. Tarsus Pharmaceuticals had a negative trailing twelve-month return on equity of 32.41% and a negative net margin of 324.99%. What ETFs hold Tarsus Pharmaceuticals' stock? ETFs with the largest weight of Tarsus Pharmaceuticals (NASDAQ:TARS) stock in their portfolio include Invesco Raymond James SB-1 Equity ETF (RYJ), ALPS Medical Breakthroughs ETF (SBIO), Principal Healthcare Innovators ETF (BTEC) and Invesco Nasdaq Biotechnology ETF (IBBQ) and When did Tarsus Pharmaceuticals IPO? (TARS) raised $80 million in an initial public offering on Friday, October 16th 2020. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James acted as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers. What is Tarsus Pharmaceuticals' stock symbol? Tarsus Pharmaceuticals trades on the NASDAQ under the ticker symbol "TARS." How do I buy shares of Tarsus Pharmaceuticals? Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Tarsus Pharmaceuticals' stock price today? One share of TARS stock can currently be purchased for approximately $12.57. How much money does Tarsus Pharmaceuticals make? Tarsus Pharmaceuticals (NASDAQ:TARS) has a market capitalization of $336.00 million and generates $25.82 million in revenue each year. The company earns $-62,090,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. How can I contact Tarsus Pharmaceuticals? The official website for the company is www.tarsusrx.com. The company can be reached via phone at 949-409-9820 or via email at ir@tarsusrx.com. This page (NASDAQ:TARS) was last updated on 4/2/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.